Clinical Trials Browser

INDUSTRY × glembatumumab vedotin × Clear all

NCT02302339 2019-09-06

A Study of Glembatumumab Vedotin as Monotherapy or in Combination With Immunotherapies in Patients With Advanced Melanoma

Phase 2 Terminated

132 enrolled 16 charts

Melanoma, Skin Neoplasms

NCT01997333 2019-03-08

METRIC

Phase 2 Completed

327 enrolled 17 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03067935 2018-05-21

Individual Patient Expanded Access-Glembatumumab Vedotin

No longer available

Metastatic gpNMB Expressing Triple Negative Breast Cancer

NCT01156753 2017-07-02

EMERGE

Phase 2 Completed

Breast Neoplasms